IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+13.69%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$849M
AUM Growth
+$849M
(-15%)
Cap. Flow
-$210M
Cap. Flow
% of AUM
-24.68%
Top 10 Holdings %
Top 10 Hldgs %
53.19%
Holding
100
New
29
Increased
13
Reduced
14
Closed
35
Top Buys
| 1 |
Inspire Medical Systems
INSP
|
$33.8M |
| 2 |
Medtronic
MDT
|
$27M |
| 3 |
Cooper Companies
COO
|
$12.1M |
| 4 |
Fresenius Medical Care
FMS
|
$9.59M |
| 5 |
Bristol-Myers Squibb
BMY
|
$9.05M |
Top Sells
| 1 |
Elevance Health
ELV
|
$43.3M |
| 2 |
Humana
HUM
|
$28M |
| 3 |
Universal Health Services
UHS
|
$24M |
| 4 |
Becton Dickinson
BDX
|
$17.5M |
| 5 |
Cigna
CI
|
$16.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Fate Therapeutics
FATE
$115M
| $3.41M | 0.38% |
975,000
+125,000
| +15% | +$438K |
|
52
Pliant Therapeutics
PLRX
$105M
| $3.36M | 0.38% |
+300,000
| New | +$3.36M |
|
53
Neurogene
NGNE
$284M
| $2.94M | 0.33% |
70,000
| – | – |
|
54
Terns Pharmaceuticals
TERN
$651M
| $2.5M | 0.28% |
+300,000
| New | +$2.5M |
|
55
Scholar Rock
SRRK
$3.3B
| $2.2M | 0.25% |
275,000
-125,000
| -31% | -$1M |
|
56
Cabaletta Bio
CABA
$144M
| $2.12M | 0.24% |
450,000
+25,000
| +6% | +$118K |
|
57
Intellia Therapeutics
NTLA
$1.26B
| $2.06M | 0.23% |
+100,000
| New | +$2.06M |
|
58
uniQure
QURE
$954M
| $1.97M | 0.22% |
+400,000
| New | +$1.97M |
|
59
GE HealthCare
GEHC
$33B
| $1.88M | 0.21% |
+20,000
| New | +$1.88M |
|
60
STAAR Surgical
STAA
$1.35B
| $1.86M | 0.21% |
+50,000
| New | +$1.86M |
|
61
Tango Therapeutics
TNGX
$745M
| $1.54M | 0.17% |
+200,000
| New | +$1.54M |
|
62
Rezolute
RZLT
$630M
| $1.21M | 0.14% |
+250,000
| New | +$1.21M |
|
63
Kyverna Therapeutics
KYTX
$161M
| $978K | 0.11% |
+200,000
| New | +$978K |
|
|
RVNC
64
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-500,000
| Closed | -$1.29M |
|
|
ITCI
65
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-145,000
| Closed | -$9.93M |
|
66
Viking Therapeutics
VKTX
$3.02B
| – | – |
-250,000
| Closed | -$13.3M |
|
|
67
Universal Health Services
UHS
$11.6B
| – | – |
-130,000
| Closed | -$24M |
|
68
Thermo Fisher Scientific
TMO
$183B
| – | – |
-25,000
| Closed | -$13.8M |
|
69
Spyre Therapeutics
SYRE
$1.02B
| – | – |
-100,000
| Closed | -$2.35M |
|
70
Repligen
RGEN
$6.54B
| – | – |
-60,000
| Closed | -$7.56M |
|
71
Insulet
PODD
$24.2B
| – | – |
-25,000
| Closed | -$5.05M |
|
72
Oscar Health
OSCR
$4.57B
| – | – |
-500,000
| Closed | -$7.91M |
|
73
Neurocrine Biosciences
NBIX
$13.5B
| – | – |
-70,000
| Closed | -$9.64M |
|
74
Merus
MRUS
$5.04B
| – | – |
-100,000
| Closed | -$5.92M |
|
75
McKesson
MCK
$85.9B
| – | – |
-20,000
| Closed | -$11.7M |
|